Tuberculosis
Tuberculosis (TB) remains a major cause of illness and death among children worldwide. Every year, more than 1 million children and young adolescents aged under 15 years of age are estimated to develop TB, and more than 150,000 die from the disease, with the highest mortality burden among children under five years of age. Despite progress in TB prevention and treatment, important gaps remain in access to effective, safe, and child-friendly medicines, particularly for the youngest children and those with drug-resistant TB.
With an increasingly rich and diverse pipeline of new TB medicines and treatment regimens, there is an unprecedented opportunity to proactively guide paediatric drug development, providing early signals to developers on priority paediatric populations, study requirements, and optimal formulation characteristics.
Building on previous PADO-TB exercises, the WHO Paediatric Drug Optimization (PADO) process in September/October 2026, held alongside the first CADO meeting for TB, aimed to identify priority needs and inform the development of optimized TB medicines for children of all ages. The joint CADO/PADO pipeline review informed priorities across age groups, supporting timely and equitable access to new treatments for children of all ages.
Portfolio products
Portfolio Update
|
|---|
|
PADO report
Contact
Email: verkuijls@who.int
Related publications
Global tuberculosis report 2026
The WHO Global tuberculosis report 2026 provides a comprehensive assessment of the tuberculosis (TB) epidemic and progress in prevention, diagnosis and...
Roadmap towards ending TB in children and adolescents, 3rd ed
The Roadmap towards ending TB among children and adolescents, third edition builds on the 2013 and 2018 versions. The 2023 version recognizes the progress...
Related links
Political declaration of the high-level meeting of the General Assembly on the fight against tuberculosis. United Nations; 2023
News